Case–control study of endogenous sex steroid hormones and risk of endometrial cancer
Background Epidemiologic evidence regarding the role of endogenous sex hormones in endometrial cancer etiology remains inconsistent. The objective of this study was to investigate if circulating levels of endogenous estrone, estradiol, sex hormone binding globulin (SHBG), testosterone, and androsten...
Gespeichert in:
| Veröffentlicht in: | Cancer causes & control 2020-02, Vol.31 (2), p.161-171 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 171 |
|---|---|
| container_issue | 2 |
| container_start_page | 161 |
| container_title | Cancer causes & control |
| container_volume | 31 |
| creator | Friedenreich, Christine M. Derksen, Jeroen W. G. Speidel, Thomas Brenner, Darren R. Heer, Emily Courneya, Kerry S. Cook, Linda S. |
| description | Background
Epidemiologic evidence regarding the role of endogenous sex hormones in endometrial cancer etiology remains inconsistent. The objective of this study was to investigate if circulating levels of endogenous estrone, estradiol, sex hormone binding globulin (SHBG), testosterone, and androstenedione are associated with endometrial cancer risk.
Methods
We conducted a population-based case–control study of 522 incident endometrial cancer cases and 976 population controls, in Alberta, Canada from 2002 to 2006. Study participants completed in-person interviews and provided fasting blood samples. Sex hormone levels were determined by enzyme-linked immunosorbent assays.
Results
Higher levels of androstenedione were associated with increased endometrial cancer risk (OR 1.44, 95% CI 1.04–2.02). Endometrial cancer risk in pre- and peri-menopausal women was reduced for the highest versus lowest quartiles of estrone (OR 0.44, 95% CI 0.22–0.88) and estradiol (OR 0.30, 95% CI 0.14–0.65), but in post-menopausal women, the endometrial cancer risk was increased for the highest versus lowest quartile of androstenedione (OR 1.82, 95% CI 1.25–2.65). In addition, endometrial cancer risk in normal/underweight women was decreased for the highest versus lowest quartile of serum SHBG (OR 0.39, 95% CI 0.19–0.84).
Conclusions
Overall, positive associations were found for androstenedione concentrations, while sub-group analyses revealed = inverse associations with estrogens and SHBG. Results of this study provide empirical evidence for the role of circulating sex hormones in endometrial cancer etiology and highlight the importance of modifiable factors that contribute to changes in sex hormone concentration levels. |
| doi_str_mv | 10.1007/s10552-019-01260-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2330064438</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2330064438</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-63001890de12bfcb2ed54a6f1d20ae320683c4ce972f35b0ccc4f194b7806daa3</originalsourceid><addsrcrecordid>eNp9kMtKxTAQhoMoery8gAspuHFTndx6WcrBGwhu1G1Ik6lW20STFnTnO_iGPonR4wVcuBgCk2_-GT5CtinsU4DyIFKQkuVA61SsgFwukRmVJc9LxuQymUEty1wywdfIeox3ACALBqtkjdOqkKLkM3I91xHfXl6Nd2PwfRbHyT5nvs3QWX-Dzk8xi_iU-hh8Z7NbHwbvMGba2Sx08f6bHXAMne4zo53BsElWWt1H3Pp6N8jV8dHl_DQ_vzg5mx-e54aXcswLDkCrGixS1rSmYWil0EVLLQONnEFRcSMM1iVruWzAGCNaWoumrKCwWvMNsrfIfQj-ccI4qqGLBvteO0ynK8bThkIIXiV09w9656fg0nWJElxUIqGJYgvKBB9jwFY9hG7Q4VlRUB_W1cK6StbVp3Ul09DOV_TUDGh_Rr41J4AvgJi-3A2G393_xL4DIIeN3w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2343484300</pqid></control><display><type>article</type><title>Case–control study of endogenous sex steroid hormones and risk of endometrial cancer</title><source>MEDLINE</source><source>Jstor Complete Legacy</source><source>Springer Nature - Complete Springer Journals</source><creator>Friedenreich, Christine M. ; Derksen, Jeroen W. G. ; Speidel, Thomas ; Brenner, Darren R. ; Heer, Emily ; Courneya, Kerry S. ; Cook, Linda S.</creator><creatorcontrib>Friedenreich, Christine M. ; Derksen, Jeroen W. G. ; Speidel, Thomas ; Brenner, Darren R. ; Heer, Emily ; Courneya, Kerry S. ; Cook, Linda S.</creatorcontrib><description>Background
Epidemiologic evidence regarding the role of endogenous sex hormones in endometrial cancer etiology remains inconsistent. The objective of this study was to investigate if circulating levels of endogenous estrone, estradiol, sex hormone binding globulin (SHBG), testosterone, and androstenedione are associated with endometrial cancer risk.
Methods
We conducted a population-based case–control study of 522 incident endometrial cancer cases and 976 population controls, in Alberta, Canada from 2002 to 2006. Study participants completed in-person interviews and provided fasting blood samples. Sex hormone levels were determined by enzyme-linked immunosorbent assays.
Results
Higher levels of androstenedione were associated with increased endometrial cancer risk (OR 1.44, 95% CI 1.04–2.02). Endometrial cancer risk in pre- and peri-menopausal women was reduced for the highest versus lowest quartiles of estrone (OR 0.44, 95% CI 0.22–0.88) and estradiol (OR 0.30, 95% CI 0.14–0.65), but in post-menopausal women, the endometrial cancer risk was increased for the highest versus lowest quartile of androstenedione (OR 1.82, 95% CI 1.25–2.65). In addition, endometrial cancer risk in normal/underweight women was decreased for the highest versus lowest quartile of serum SHBG (OR 0.39, 95% CI 0.19–0.84).
Conclusions
Overall, positive associations were found for androstenedione concentrations, while sub-group analyses revealed = inverse associations with estrogens and SHBG. Results of this study provide empirical evidence for the role of circulating sex hormones in endometrial cancer etiology and highlight the importance of modifiable factors that contribute to changes in sex hormone concentration levels.</description><identifier>ISSN: 0957-5243</identifier><identifier>EISSN: 1573-7225</identifier><identifier>DOI: 10.1007/s10552-019-01260-5</identifier><identifier>PMID: 31865473</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>17β-Estradiol ; Aged ; Alberta - epidemiology ; Androstenedione ; Biomedical and Life Sciences ; Biomedicine ; Cancer ; Cancer Research ; Case-Control Studies ; Empirical analysis ; Endometrial cancer ; Endometrial Neoplasms - epidemiology ; Endometrium ; Epidemiology ; Estrogens ; Estrone ; Etiology ; Female ; Globulins ; Gonadal Steroid Hormones - blood ; Health risk assessment ; Health risks ; Hematology ; Hormone replacement therapy ; Hormones ; Humans ; Immunoassays ; Menopause ; Middle Aged ; Oncology ; Original Paper ; Population studies ; Post-menopause ; Prospective Studies ; Public Health ; Quartiles ; Risk ; Sex Hormone-Binding Globulin - analysis ; Sex hormones ; Steroid hormones ; Steroids ; Testosterone ; Underweight</subject><ispartof>Cancer causes & control, 2020-02, Vol.31 (2), p.161-171</ispartof><rights>Springer Nature Switzerland AG 2019</rights><rights>Cancer Causes & Control is a copyright of Springer, (2019). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-63001890de12bfcb2ed54a6f1d20ae320683c4ce972f35b0ccc4f194b7806daa3</citedby><cites>FETCH-LOGICAL-c375t-63001890de12bfcb2ed54a6f1d20ae320683c4ce972f35b0ccc4f194b7806daa3</cites><orcidid>0000-0002-4783-1966</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10552-019-01260-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10552-019-01260-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31865473$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Friedenreich, Christine M.</creatorcontrib><creatorcontrib>Derksen, Jeroen W. G.</creatorcontrib><creatorcontrib>Speidel, Thomas</creatorcontrib><creatorcontrib>Brenner, Darren R.</creatorcontrib><creatorcontrib>Heer, Emily</creatorcontrib><creatorcontrib>Courneya, Kerry S.</creatorcontrib><creatorcontrib>Cook, Linda S.</creatorcontrib><title>Case–control study of endogenous sex steroid hormones and risk of endometrial cancer</title><title>Cancer causes & control</title><addtitle>Cancer Causes Control</addtitle><addtitle>Cancer Causes Control</addtitle><description>Background
Epidemiologic evidence regarding the role of endogenous sex hormones in endometrial cancer etiology remains inconsistent. The objective of this study was to investigate if circulating levels of endogenous estrone, estradiol, sex hormone binding globulin (SHBG), testosterone, and androstenedione are associated with endometrial cancer risk.
Methods
We conducted a population-based case–control study of 522 incident endometrial cancer cases and 976 population controls, in Alberta, Canada from 2002 to 2006. Study participants completed in-person interviews and provided fasting blood samples. Sex hormone levels were determined by enzyme-linked immunosorbent assays.
Results
Higher levels of androstenedione were associated with increased endometrial cancer risk (OR 1.44, 95% CI 1.04–2.02). Endometrial cancer risk in pre- and peri-menopausal women was reduced for the highest versus lowest quartiles of estrone (OR 0.44, 95% CI 0.22–0.88) and estradiol (OR 0.30, 95% CI 0.14–0.65), but in post-menopausal women, the endometrial cancer risk was increased for the highest versus lowest quartile of androstenedione (OR 1.82, 95% CI 1.25–2.65). In addition, endometrial cancer risk in normal/underweight women was decreased for the highest versus lowest quartile of serum SHBG (OR 0.39, 95% CI 0.19–0.84).
Conclusions
Overall, positive associations were found for androstenedione concentrations, while sub-group analyses revealed = inverse associations with estrogens and SHBG. Results of this study provide empirical evidence for the role of circulating sex hormones in endometrial cancer etiology and highlight the importance of modifiable factors that contribute to changes in sex hormone concentration levels.</description><subject>17β-Estradiol</subject><subject>Aged</subject><subject>Alberta - epidemiology</subject><subject>Androstenedione</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer</subject><subject>Cancer Research</subject><subject>Case-Control Studies</subject><subject>Empirical analysis</subject><subject>Endometrial cancer</subject><subject>Endometrial Neoplasms - epidemiology</subject><subject>Endometrium</subject><subject>Epidemiology</subject><subject>Estrogens</subject><subject>Estrone</subject><subject>Etiology</subject><subject>Female</subject><subject>Globulins</subject><subject>Gonadal Steroid Hormones - blood</subject><subject>Health risk assessment</subject><subject>Health risks</subject><subject>Hematology</subject><subject>Hormone replacement therapy</subject><subject>Hormones</subject><subject>Humans</subject><subject>Immunoassays</subject><subject>Menopause</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Original Paper</subject><subject>Population studies</subject><subject>Post-menopause</subject><subject>Prospective Studies</subject><subject>Public Health</subject><subject>Quartiles</subject><subject>Risk</subject><subject>Sex Hormone-Binding Globulin - analysis</subject><subject>Sex hormones</subject><subject>Steroid hormones</subject><subject>Steroids</subject><subject>Testosterone</subject><subject>Underweight</subject><issn>0957-5243</issn><issn>1573-7225</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kMtKxTAQhoMoery8gAspuHFTndx6WcrBGwhu1G1Ik6lW20STFnTnO_iGPonR4wVcuBgCk2_-GT5CtinsU4DyIFKQkuVA61SsgFwukRmVJc9LxuQymUEty1wywdfIeox3ACALBqtkjdOqkKLkM3I91xHfXl6Nd2PwfRbHyT5nvs3QWX-Dzk8xi_iU-hh8Z7NbHwbvMGba2Sx08f6bHXAMne4zo53BsElWWt1H3Pp6N8jV8dHl_DQ_vzg5mx-e54aXcswLDkCrGixS1rSmYWil0EVLLQONnEFRcSMM1iVruWzAGCNaWoumrKCwWvMNsrfIfQj-ccI4qqGLBvteO0ynK8bThkIIXiV09w9656fg0nWJElxUIqGJYgvKBB9jwFY9hG7Q4VlRUB_W1cK6StbVp3Ul09DOV_TUDGh_Rr41J4AvgJi-3A2G393_xL4DIIeN3w</recordid><startdate>20200201</startdate><enddate>20200201</enddate><creator>Friedenreich, Christine M.</creator><creator>Derksen, Jeroen W. G.</creator><creator>Speidel, Thomas</creator><creator>Brenner, Darren R.</creator><creator>Heer, Emily</creator><creator>Courneya, Kerry S.</creator><creator>Cook, Linda S.</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4783-1966</orcidid></search><sort><creationdate>20200201</creationdate><title>Case–control study of endogenous sex steroid hormones and risk of endometrial cancer</title><author>Friedenreich, Christine M. ; Derksen, Jeroen W. G. ; Speidel, Thomas ; Brenner, Darren R. ; Heer, Emily ; Courneya, Kerry S. ; Cook, Linda S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-63001890de12bfcb2ed54a6f1d20ae320683c4ce972f35b0ccc4f194b7806daa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>17β-Estradiol</topic><topic>Aged</topic><topic>Alberta - epidemiology</topic><topic>Androstenedione</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer</topic><topic>Cancer Research</topic><topic>Case-Control Studies</topic><topic>Empirical analysis</topic><topic>Endometrial cancer</topic><topic>Endometrial Neoplasms - epidemiology</topic><topic>Endometrium</topic><topic>Epidemiology</topic><topic>Estrogens</topic><topic>Estrone</topic><topic>Etiology</topic><topic>Female</topic><topic>Globulins</topic><topic>Gonadal Steroid Hormones - blood</topic><topic>Health risk assessment</topic><topic>Health risks</topic><topic>Hematology</topic><topic>Hormone replacement therapy</topic><topic>Hormones</topic><topic>Humans</topic><topic>Immunoassays</topic><topic>Menopause</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Original Paper</topic><topic>Population studies</topic><topic>Post-menopause</topic><topic>Prospective Studies</topic><topic>Public Health</topic><topic>Quartiles</topic><topic>Risk</topic><topic>Sex Hormone-Binding Globulin - analysis</topic><topic>Sex hormones</topic><topic>Steroid hormones</topic><topic>Steroids</topic><topic>Testosterone</topic><topic>Underweight</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Friedenreich, Christine M.</creatorcontrib><creatorcontrib>Derksen, Jeroen W. G.</creatorcontrib><creatorcontrib>Speidel, Thomas</creatorcontrib><creatorcontrib>Brenner, Darren R.</creatorcontrib><creatorcontrib>Heer, Emily</creatorcontrib><creatorcontrib>Courneya, Kerry S.</creatorcontrib><creatorcontrib>Cook, Linda S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer causes & control</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Friedenreich, Christine M.</au><au>Derksen, Jeroen W. G.</au><au>Speidel, Thomas</au><au>Brenner, Darren R.</au><au>Heer, Emily</au><au>Courneya, Kerry S.</au><au>Cook, Linda S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Case–control study of endogenous sex steroid hormones and risk of endometrial cancer</atitle><jtitle>Cancer causes & control</jtitle><stitle>Cancer Causes Control</stitle><addtitle>Cancer Causes Control</addtitle><date>2020-02-01</date><risdate>2020</risdate><volume>31</volume><issue>2</issue><spage>161</spage><epage>171</epage><pages>161-171</pages><issn>0957-5243</issn><eissn>1573-7225</eissn><abstract>Background
Epidemiologic evidence regarding the role of endogenous sex hormones in endometrial cancer etiology remains inconsistent. The objective of this study was to investigate if circulating levels of endogenous estrone, estradiol, sex hormone binding globulin (SHBG), testosterone, and androstenedione are associated with endometrial cancer risk.
Methods
We conducted a population-based case–control study of 522 incident endometrial cancer cases and 976 population controls, in Alberta, Canada from 2002 to 2006. Study participants completed in-person interviews and provided fasting blood samples. Sex hormone levels were determined by enzyme-linked immunosorbent assays.
Results
Higher levels of androstenedione were associated with increased endometrial cancer risk (OR 1.44, 95% CI 1.04–2.02). Endometrial cancer risk in pre- and peri-menopausal women was reduced for the highest versus lowest quartiles of estrone (OR 0.44, 95% CI 0.22–0.88) and estradiol (OR 0.30, 95% CI 0.14–0.65), but in post-menopausal women, the endometrial cancer risk was increased for the highest versus lowest quartile of androstenedione (OR 1.82, 95% CI 1.25–2.65). In addition, endometrial cancer risk in normal/underweight women was decreased for the highest versus lowest quartile of serum SHBG (OR 0.39, 95% CI 0.19–0.84).
Conclusions
Overall, positive associations were found for androstenedione concentrations, while sub-group analyses revealed = inverse associations with estrogens and SHBG. Results of this study provide empirical evidence for the role of circulating sex hormones in endometrial cancer etiology and highlight the importance of modifiable factors that contribute to changes in sex hormone concentration levels.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>31865473</pmid><doi>10.1007/s10552-019-01260-5</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-4783-1966</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0957-5243 |
| ispartof | Cancer causes & control, 2020-02, Vol.31 (2), p.161-171 |
| issn | 0957-5243 1573-7225 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2330064438 |
| source | MEDLINE; Jstor Complete Legacy; Springer Nature - Complete Springer Journals |
| subjects | 17β-Estradiol Aged Alberta - epidemiology Androstenedione Biomedical and Life Sciences Biomedicine Cancer Cancer Research Case-Control Studies Empirical analysis Endometrial cancer Endometrial Neoplasms - epidemiology Endometrium Epidemiology Estrogens Estrone Etiology Female Globulins Gonadal Steroid Hormones - blood Health risk assessment Health risks Hematology Hormone replacement therapy Hormones Humans Immunoassays Menopause Middle Aged Oncology Original Paper Population studies Post-menopause Prospective Studies Public Health Quartiles Risk Sex Hormone-Binding Globulin - analysis Sex hormones Steroid hormones Steroids Testosterone Underweight |
| title | Case–control study of endogenous sex steroid hormones and risk of endometrial cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T12%3A46%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Case%E2%80%93control%20study%20of%20endogenous%20sex%20steroid%20hormones%20and%20risk%20of%20endometrial%20cancer&rft.jtitle=Cancer%20causes%20&%20control&rft.au=Friedenreich,%20Christine%20M.&rft.date=2020-02-01&rft.volume=31&rft.issue=2&rft.spage=161&rft.epage=171&rft.pages=161-171&rft.issn=0957-5243&rft.eissn=1573-7225&rft_id=info:doi/10.1007/s10552-019-01260-5&rft_dat=%3Cproquest_cross%3E2330064438%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2343484300&rft_id=info:pmid/31865473&rfr_iscdi=true |